The oncobiome; what, so what, now what?

Microbiome Research Reports, Journal Year: 2025, Volume and Issue: 4(1)

Published: Feb. 27, 2025

Microbial communities inhabiting various body sites play critical roles in the initiation, progression, and treatment of cancer. The gut microbiota, a highly diverse microbial ecosystem, interacts with immune cells to modulate inflammation surveillance, influencing cancer risk therapeutic outcomes. Local tissue microbiota may impact transition from premalignant states malignancy. Characterization intratumoral increasingly reveals distinct microbiomes that influence tumor growth, responses, efficacy. Various bacteria species have been reported therapies through mechanisms such as altering drug metabolism shaping microenvironment (TME). For instance, or bacterial enzymatic activity can convert prodrugs into active forms, enhancing effects or, conversely, inactivating small-molecule chemotherapeutics. Specific also linked improved responses immunotherapy, underscoring microbiome’s role Furthermore, unique signatures patients, compared healthy individuals, demonstrate diagnostic potential microbiota. Beyond gut, tumor-associated local affect therapy by inflammation, resistance. This review explores multifaceted relationships between cancer, focusing on their modulating TME, activation, members represents promising avenue for advancing precision oncology improving patient By leveraging biomarkers interventions, new strategies be developed optimize diagnosis treatment.

Language: Английский

The functional extracellular vesicles target tumor microenvironment for gastrointestinal malignancies therapy

Extracellular Vesicle, Journal Year: 2025, Volume and Issue: 5, P. 100077 - 100077

Published: April 6, 2025

Language: Английский

The role of epigenetic regulation in pancreatic ductal adenocarcinoma progression and drug response: an integrative genomic and pharmacological prognostic prediction model

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Nov. 21, 2024

Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with poor prognosis. Epigenetic dysregulation plays crucial role in PDAC progression, but its comprehensive landscape and clinical implications remain unclear.

Language: Английский